What clinics reported offering
A study in West Virginia and Oklahoma identified 75 clinics and medical spas that offered compounded GLP-1 drugs. Of those, 42 offered products with B vitamins (56%). The study of post-shortage sourcing also traced suppliers. The researchers checked those businesses and suppliers in two states, so the figures do not estimate how often B vitamins are added nationwide[1].
The study recorded products, rather than assessing why a clinician might prescribe B12 to a particular patient. FDA says the safety and effectiveness of combining semaglutide with added ingredients such as B12 have not been established[3].
What the tirzepatide samples showed
Researchers employed by Eli Lilly identified an impurity in tested compounded tirzepatide and B12 products. They attributed it to a reaction between tirzepatide and certain forms of B12 [2]. That analysis did not test semaglutide combinations or measure outcomes in patients.
Laboratory impurity testing and the dosing errors reported to poison centers answer different safety questions. The first measures what is in sampled products. The second tracks reports of what happened when people took a dose.
What to ask about a prescription
The guide to compounded semaglutide safety explains how FDA review differs for approved and compounded drugs. If a prescription includes an added ingredient, ask the prescriber why it is included and ask the dispensing pharmacist to confirm the ingredients and concentration.
FDA has received reports of dosing errors with compounded injectable semaglutide. Clarify the dose and measurement with the prescriber or pharmacist before using it[3].